GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nuvation Bio NUVB · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.35

+4.57%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$62.9m

FY2018FY2025

Net income

−$204.6m

FY2018FY2025

Free cash flow

−$173.8m

FY2018FY2025

Shareholders' equity

$305.7m

FY2018FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$62.9m$7.9m——————
Gross profit$54.5m$795,000−$222,000−$484,000−$368,000−$103,000——
Research and development$115.1m$524.2m$71.3m$87.8m$69.0m$32.6m$25.1m$482,667
Operating income−$213.1m−$592.6m−$99.8m−$119.7m−$93.3m−$43.6m−$32.1m−$992,000
Net income−$204.6m−$567.9m−$75.8m−$104.2m−$86.8m−$41.7m−$33.6m−$992,000
Diluted earnings per share-0.59-1.69-0.35-0.48-0.43-0.31-0.14-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets$594.8m$540.6m$621.5m$672.1m$776.2m$221.8m$121.0m$158,000
Cash and short-term investments$529.2m$502.7m$611.2m$661.0m$765.4m$215.8m$118.9m$138,000
Total liabilities$289.1m$76.8m$16.4m$17.1m$30.2m$6.7m$3.2m$902,000
Debt$54.8m$6.3m—————$600,000
Shareholders' equity$305.7m$463.8m$605.1m$655.1m$746.0m$215.1m$117.7m−$744,000
Shares outstanding344m337m219m218m202m134m237m184m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−$173.4m−$130.4m−$68.0m−$96.1m−$68.2m−$36.5m−$24.4m−$616,000
Capital spending−$354,000−$162,000−$69,000−$370,000−$282,000−$145,000−$659,000−$659,000
Free cash flow−$173.8m−$130.6m−$68.1m−$96.5m−$68.5m−$36.7m−$25.1m−$1.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$31.7m$83.2m$41.9m$13.1m$4.8m$3.1m$5.7m$727,000
Gross profit$30.8m$77.6m$41.4m$9.8m$2.3m$990,000$1.5m−$788,000
Operating income−$56.1m$5.5m−$35.2m−$56.4m−$63.6m−$59.0m−$53.9m−$48.1m
Net income−$62.8m$5.4m−$36.6m−$55.8m−$59.0m−$53.2m−$49.4m−$41.2m
Diluted earnings per share-0.180.02-0.11-0.16-0.17-0.15-0.15-0.12
Cash from operations−$5.0m$5.0m−$29.0m−$52.0m−$48.0m−$42.0m−$46.0m−$31.0m
Total assets$744.5m$610.2m$594.8m$601.6m$647.2m$492.5m$540.6m$571.6m
Cash and short-term investments$661.0m$533.7m$529.2m$549.0m$607.7m$461.7m$502.7m$549.1m
Debt$250.2m$55.0m$54.8m$54.6m$54.4m$7.6m$7.9m$10.2m
Shareholders' equity$253.9m$319.6m$305.7m$325.9m$372.9m$419.5m$463.8m$502.7m

Financial ratios

Data as of 30 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Gross margin86.6%10.1%—————
Operating margin-303.6%-7209.4%—————
Net margin-325.3%-7213.8%—————
Return on equity-66.9%-122.5%-12.5%-15.9%-11.6%-19.4%—
Return on assets-34.4%-105.1%-12.2%-15.5%-11.2%-18.8%—
Free cash flow yield-10.5%-8.1%-6.5%-9.2%-7.0%-5.7%—
Revenue growth699.0%——————
Earnings growth-64.0%649.2%-27.3%20.0%108.5%24.2%—
Current ratio6.95x9.04x44.11x50.70x45.62x33.69x—
Debt to equity0.18x0.02x0.00x0.00x0.00x—-0.81x
Equity ratio51.4%85.8%97.4%97.5%96.1%97.0%—
Interest coverage-13.96x-1664.51x—-11.38x-134.86x——
R&D as a share of sales183.0%6658.1%—————
Buybacks as a share of market value-2.2%-53.9%-0.2%-7.9%-51.6%43.7%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income21.2%37.4%—
Net income25.2%37.5%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin78.1%———
Operating margin-1138.4%———
Net margin-1091.6%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-15.1-1.6-4.4-4.0-19.8-37.5
Price to sales49.0113.8————

Market value over time

31 Aug 2020 to 29 Oct 2026, in USD

$890.0m$1.66bn

Share price return

Finished calendar years

202520242023202220212020
Return244%80%-14%-79%-21%6%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.